Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

AZD8186 First Time In Patient Ascending Dose Study

Complete title: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186

Research Study Number 20131275
Principal Investigator Tia Higano, MD
Phase I

Research Study Description

This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer (sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient advanced solid malignancies. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of the patients.

There are two parts to this study: Part A, dose escalation, and Part B, expansion cohort(s) at the intended therapeutic dose(s).

Eligibility Criteria (must meet the following to participate in this study)

- * For Eligibility information, please click on the "Look up trial at NIH" link above.

Other eligibility criteria may apply.

Research Study Number 20131275
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Breast Cancer; Genitourinary Cancer; Lung Cancer; Prostate Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials